Physician profile
David Branyon
NPI 1568415297
$653.80
in general payments reported to CMS, 2019-2025
8 companies · $47.03 in 2025
The $47.03 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $97.79 · 2021: $130 · 2022: $40.45 · 2023: $152 · 2024: $14.53 · 2025: $47.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $214.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $266.77 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $165.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $71.21 | 2019-2023 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $56.34 | 2020-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $36.90 | 2019-2021 | |
| Alkermes, INC. | $36.36 | 2021-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $11.13 | 2019 | |
| Neuronetics, INC. | $9.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Branyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.